Drug intelligence / Profile preview

cyclophosphamide + nab paclitaxel + trastuzumab

Development stage: Unknown
Lead developer: Takeda
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is a combination chemotherapy regimen used primarily for the treatment of HER2-positive breast cancer. The combination includes: 1. Cyclophosphamide - an alkylating agent that works by damaging DNA and preventing cancer cells from dividing 2. Nab paclitaxel (albumin-bound paclitaxel) - a taxane that disrupts microtubule function during cell division 3. Trastuzumab (Herceptin) - a monoclonal antibody that targets the HER2 protein on cancer cells This combination may be used in both early-stage and metastatic HER2-positive breast cancer settings.

Targets

DNA

Beyond the preview

Go deeper on cyclophosphamide + nab paclitaxel + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + nab paclitaxel + trastuzumab.

Explore the full profile